Skip Navigation Links.
Collapse <span class="m110 colortj mt20 fontw700">Volume 12 (2024)</span>Volume 12 (2024)
Collapse <span class="m110 colortj mt20 fontw700">Volume 11 (2023)</span>Volume 11 (2023)
Collapse <span class="m110 colortj mt20 fontw700">Volume 10 (2022)</span>Volume 10 (2022)
Collapse <span class="m110 colortj mt20 fontw700">Volume 9 (2021)</span>Volume 9 (2021)
Collapse <span class="m110 colortj mt20 fontw700">Volume 8 (2020)</span>Volume 8 (2020)
Collapse <span class="m110 colortj mt20 fontw700">Volume 7 (2019)</span>Volume 7 (2019)
Collapse <span class="m110 colortj mt20 fontw700">Volume 6 (2018)</span>Volume 6 (2018)
Collapse <span class="m110 colortj mt20 fontw700">Volume 5 (2017)</span>Volume 5 (2017)
Collapse <span class="m110 colortj mt20 fontw700">Volume 4 (2016)</span>Volume 4 (2016)
Collapse <span class="m110 colortj mt20 fontw700">Volume 3 (2015)</span>Volume 3 (2015)
Collapse <span class="m110 colortj mt20 fontw700">Volume 2 (2014)</span>Volume 2 (2014)
Collapse <span class="m110 colortj mt20 fontw700">Volume 1 (2013)</span>Volume 1 (2013)
American Journal of Medical Case Reports. 2022, 10(8), 207-209
DOI: 10.12691/AJMCR-10-8-8
Case Report

Unusual Presentation of Primary Extra Nodal Diffuse Large B Cell Lymphoma

Yaqub Nadeem Mohammed1, Folake Ishola1, 2 and Geetha Krishnamoorthy1,

1Department of Internal Medicine, St. Joseph Mercy Oakland Hospital, Michigan, USA

2Ross University School of Medicine, Florida, USA

Pub. Date: August 21, 2022
Full Text PDF

Cite this paper

Yaqub Nadeem Mohammed, Folake Ishola and Geetha Krishnamoorthy. Unusual Presentation of Primary Extra Nodal Diffuse Large B Cell Lymphoma. American Journal of Medical Case Reports. 2022; 10(8):207-209. doi: 10.12691/AJMCR-10-8-8

Abstract

Diffuse Large B Cell Lymphoma (DLBCL) is the most frequently occurring type of Non-Hodgkin Lymphoma (NHL). Primary extra nodal Diffuse Large B Cell Lymphoma (PE-DLBCL) originating in the bone, specifically the thoracic spine, is rare. We describe the case of a 69-year-old male who presented to our facility with back pain and acute bilateral lower extremity paraplegia as Primary extra nodal Diffuse Large B Cell Lymphoma.

Keywords

R-CHOP chemotherapy, Primary Extra nodal Diffuse Large B-cell Lymphoma (PE-DLBCL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B Cell Lymphoma (DLBCL), Extra nodal Diffuse Large B-cell Lymphoma

Copyright

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]  Li, S., Young, K.H., and Medeiros, L.J. “Diffuse large B-cell lymphoma,” Pathology, 50(1). 74-87. January 2018.
 
[2]  Vitolo, U., Seymour, J.F., Martelli, M., Illerhaus, G., Illidge, T., Zucca, E., Campo, E., and Ladetto, M. “Extra nodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up,” Annals of Oncology, 27(9). 91-102. September 2016.
 
[3]  Shen, H., Wei, Z., Zhou, D., Zhang, Y., Han, X., Wang, W., and Feng, J. “Primary extra nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients,” Oncology Letters, 16(2). 1602-1614. May 2018.
 
[4]  Song, J.Y., Perry, A.M., Herrera, A.F., Chen, L., Skrabek, P., Nasr, M.R., Ottesen, R.A., Nikowitz, J., Bedell, V., Murata-Collins, J., Li, Y., McCarthy, C., Pillai, R., Wang, J., Wu, X., Zain, J., Popplewell, L., Kwak, L.W., Nademanee, A.P., Niland, J.C., and Weisenburger, D.D. “Double-hit signature with TP53 abnormalities predicts poor survival in patients with Germinal Center Type Diffuse Large B-cell Lymphoma treated with R-CHOP,” Clinical cancer research: an official journal of the American Association for Cancer Research, 27(6), 1671-1680. March 2021.
 
[5]  Lim, C.Y., and Ong, K.O. “Imaging of musculoskeletal lymphoma.” Cancer imaging: the official publication of the International Cancer Imaging Society, 13(4), 448-457. December 2013.
 
[6]  Seo, J. Y., Ha, K. Y., Kim, M. U., Kim, Y. C., and Kim, Y. H. “Spinal cord compression by B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a patient seropositive for human immunodeficiency virus: a case report.” Journal of medical case reports, 8(324). October 2014.
 
[7]  Moussaly, E., Nazha, B., Zaarour, M., and Atallah, J.P. “Primary Non-Hodgkin's Lymphoma of the Spine: A Case Report and Literature Review.” World journal of oncology, 6(5), 459-463. October 2015.
 
[8]  Chang, C.M., Chen, H.C., Yang, Y., Wang, R.C., Hwang, W.L., and Teng, C. L. “Surgical decompression improves recovery from neurological deficit and may provide a survival benefit in patients with diffuse large B-cell lymphoma-associated spinal cord compression: a case-series study.” World journal of surgical oncology, 11(90). April 2013.
 
[9]  Freedman, A.S, and Friedberg, J.W. “Initial treatment of advanced stage diffuse large B cell lymphoma,” UpToDate, [Online]. Available https://www.uptodate.com/contents/initial-treatment-of-advanced-stage-diffuse-large-b-cell-lymphoma?search=Initial%20treatment%20of%20advanced%20stage%20diffuse%20large% 20B%20cell%20lymphoma &source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1 [Accessed July 15, 2021].
 
[10]  Susanibar-Adaniya, S., and Barta, S.K. “2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management,” American journal of hematology, 96(5), 617-629. March 2021.
 
[11]  Cunningham, D., Hawkes, E.A., Jack, A., Qian, W., Smith, P., Mouncey, P., Pocock, C., Ardeshna, K.M., Radford, J.A., McMillan, A., Davies, J., Turner, D., Kruger, A., Johnson, P., Gambell, J., and Linch, D. “Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles,” Lancet (London, England), 381(9880), 1817-1826. April 2013.
 
[12]  Nastoupil, L.J., Rose, A.C., and Flowers, C.R. “Diffuse large B-cell lymphoma: current treatment approaches,” Oncology (Williston Park, N.Y.), 26(5), 488-495. May 2012.
 
[13]  Delarue, R., Tilly, H., Mounier, N., Petrella, T., Salles, G., Thieblemont, C., Bologna, S., Ghesquières, H., Hacini, M., Fruchart, C., Ysebaert, L., Fermé, C., Casasnovas, O., Van Hoof, A., Thyss, A., Delmer, A., Fitoussi, O., Molina, T. J., Haioun, C., and Bosly, A. “Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial,” The Lancet. Oncology, 14(6), 525-533. April 2013.
 
[14]  Li, X., Huang, H., Xu, B., Guo, H., Lin, Y., Ye, S., Yi, J., Li, W., Wu, X., Wang, W., Zhan, H., Xie, D., Peng, J., Cao, Y., Pu, X., Guo, C., Hong, H., Wang, Z., Fang, X., Zhou, Y., and Lin, T. “Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial,” Cancer research and treatment, 51(3), 919-932. October 2018.
 
[15]  He, Y., Tao, W., Ji, D., Lu, W., Xiong, Y., and Chen, G. “RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis,” Translational cancer research, 10(5), 2044-2054. May 2021.
 
[16]  Freedman, A. S., and Aster, J.C. “Prognosis of diffuse Large B Cell Lymphoma,” UpToDate, [Online]. Available https://www.uptodate.com/contents/prognosis-of-diffuse-large-b-cell-lymphoma?search=Prognosis%20of%20diffuse%20Large%20B%20Cell% 20Lymphoma.&source=search_result&selectedTitle=1 ~123&usage_type=default&display_rank=1 [Accessed July 15, 2021].